Republicans leave town with no clear path on Obamacare
Jennifer Haberkorn and Paul Demko, Politico
Republicans are leaving Washington Thursday for a month of recess with no clear direction on what they’ll do next on Obamacare. Senate leaders want to just drop the issue altogether. Conservatives say they’re still fighting for repeal. Moderates want to launch a bipartisan effort to fix the shaky Obamacare system.
Bipartisan moves to steady insurance market face same old conflicts over regulation
Harris Meyer, Modern Healthcare
Fledgling efforts in the Senate and U.S. House of Representatives to develop bipartisan legislation to stabilize the individual insurance market could founder over clashing views on deregulating health plans. Democrats and a growing number of Republicans are eager to steady the struggling individual market covering nearly 20 million Americans to prevent an exodus of insurers and healthy customers.
Big Tobacco Won’t Let the FDA Cut Nicotine Without a Fight
Anna Edney and Jennifer Kaplan, Bloomberg
In 2009 a Democratic Congress and president gave the U.S. Food and Drug Administration the power to regulate tobacco. Eight years later, under a White House and Congress controlled by Republicans, the FDA made its strongest use of that authority.
Finance Committee announces healthcare hearing in September
Peter Sullivan, The Hill
Senate Finance Committee Chairman Orrin Hatch (R-Utah) announced Thursday that the panel will hold a healthcare hearing in September, in the wake of a failed vote on repeal of ObamaCare. The hearing will be a chance for members of both parties to discuss the healthcare law, and it comes amid calls for a return to regular order and the committee process.
U.S. scientists edit genome of human embryo, but cast doubt on possibility of ‘designer babies’
Sharon Begley, Stat News
Creating “designer babies” with a revolutionary new genome-editing technique would be extremely difficult, according to the first U.S. experiment that tried to replace a disease-causing gene in a viable human embryo. Partial results of the study had leaked out last week, ahead of its publication in Nature on Wednesday, stirring critics’ fears that genes for desired traits — from HIV resistance to strong muscles — might soon be easily slipped into embryos. In fact, the researchers found the opposite: They were unable to insert a lab-made gene.
Stocks Drift Before U.S. Jobs Data; Euro Advances: Markets Wrap
Robert Brand and Eddie Van Der Walt, Bloomberg
European and Asian stocks drifted and bonds were mixed as investors pondered the latest drama in Washington while they wait for new clues on the U.S. economy. The euro hit a fresh two-and-a-half year high against the dollar and oil retreated.
Insurers Think They’ve Found the Perfect Patients for Profits
Zachary Tracer, Bloomberg
The turmoil around the Affordable Care Act has created heartburn for health insurers. The industry is betting that a different government program will soothe its ills.
Employer-based health coverage likely to stay awhile
Laurie Kellman and Joyce M. Rosenberg, The Associated Press
Get your insurance through your employer? The ongoing political turmoil around “Obamacare” all but guarantees you’ll still be able to do that.
University of Chicago Medicine severs ties with Medicaid insurer IlliniCare
Lisa Schencker, Chicago Tribune
Thousands of low-income patients may have to scramble to find new doctors this month after University of Chicago Medicine became the latest major health system to break up with IlliniCare Health, an insurer that administers benefits for the state’s Medicaid program. U. of C. Medicine follows Northwestern Medicine and Advocate Health Care in walking away from IlliniCare Health, one of 12 Medicaid managed care organizations in the state.
Behind Kaiser’s $1 billion quarterly operating gain, and how it might repeat it
Dave Barkholz, Modern Healthcare
Kaiser Permanente will be tested to repeat the record $1 billion in operating income it posted in the first quarter. After all, the Oakland, Calif.-based hospital and managed-care giant is swimming against the same national trends that dented the earnings of investor-owned hospital chains in the second quarter.
Under Trump, Hospitals Face Same Penalties Embraced By Obama
Jordan Rau, Kaiser Health News
Amid all the turbulence over the future of the Affordable Care Act, one facet continues unchanged: President Donald Trump’s administration is penalizing more than half the nation’s hospitals for having too many patients return within a month. Medicare is punishing 2,573 hospitals, just two dozen short of what it did last year under former President Barack Obama, according to federal records released Wednesday.
The goods buried within Medicare’s hospital rule
Bob Herman, Axios
Medicare’s final 2018 hospital payment rule set in stone a spate of policies — ranging from a withdrawn proposal that would have required accrediting bodies to make confidential hospital inspections public to a new (and unpopular) system for calculating hospitals’ uncompensated care. But a handful of other payment policy changes also will go into effect next year, pleasing the various companies and industries that lobbied the Centers for Medicare and Medicaid Services.
Pharma, Biotech and Devices
Wal-Mart, Walgreens, CVS turn up the heat on generic drugmaker deals
Deena Beasley, Reuters
The largest U.S. retail pharmacies, including Wal-Mart Stores Inc and Walgreens Boots Alliance Inc, are wielding more leverage when buying generic drugs, accelerating a decline in prices likely to affect drug companies for some time, industry experts said on Thursday. That pressure is exacerbated by efforts from U.S. health regulators to speed approval of copycat drugs, industry sources said.
Senate Passes F.D.A. Funding and ‘Right to Try’ Drug Bills
Robert Pear and Sheila Kaplan, The New York Times
The Senate on Thursday gave final approval to legislation to finance the Food and Drug Administration, clearing the measure for President Trump and tapping drug manufacturers once again to help pay for the federal review of prescription drugs and medical devices. The 94-to-1 vote came just hours after the Senate passed a separate bill expanding access to experimental treatments for people with terminal illnesses.
Regeneron beats profit view, to end antibody deal with Sanofi
Natalie Grover and Manas Mishra, Reuters
Regeneron Pharmaceuticals Inc reported a much better-than-expected quarterly profit on strong demand for its flagship Eylea drug and said it would end one of its agreements with France’s Sanofi SA to develop antibodies by the end of the year. Shares of Regeneron, which also raised its full-year growth forecast for the eye treatment, closed down 2 percent at $467.11 on Thursday.
Hospitals brace for security risks that could come with using wearables for patient care
Max Blau, Stat News
Hailed as the future of preventive care, wearable health devices allow doctors to keep closer tabs on the health of patients as they go about their daily routines. But as health systems consider these medical-grade devices, hoping to lower costs associated with hospital readmissions, they have also raised concerns about potential security risks to patients and to the hospitals connected with them.
A Message from PhRMA:
Myth: U.S. government would make sure medicines are safe. Fact: The government has authority to allow drug importation if the secretary of HHS certifies imports would not threaten the health and safety of Americans and would generate cost savings for consumers. No secretary has been able to do that. Allowing the importation of drugs from other countries into the U.S. would lead to potentially dangerous outcomes for patients and increase the burden on law enforcement to prevent unregulated medicines from harming Americans. Get the facts at http://onphr.ma/2u12plT
Opinions, Editorials and Perspectives
The Health Care Solutions Small Businesses Need
Mike Roach and Nancy Clark, Morning Consult
Republican plans to repeal the Affordable Care Act were like something out of a B horror movie: terrifying at times, very unrealistic and surprisingly difficult to kill. Fortunately for America’s small businesses, conservative lawmakers failed for now to gut the ACA.
Let’s Stop the Bickering and Fix the Health Care System
Josh Gottheimer and Tom Reed, The New York Times
If either of us were building the American health care system from scratch, we’d probably end up in different places. We have contrasting ideas — one of us is a Democrat, the other a Republican — about what ails the system and how to reshape it.
The opioid epidemic, explained
German Lopez, Vox
If nothing is done, we can expect a lot of people to die: A forecast by STAT concluded that as many as 650,000 people will die over the next 10 years from opioid overdoses — more than the entire city of Baltimore. The US risks losing the equivalent of a whole American city in just one decade.